Organon & Co. (NYSE:OGN – Get Free Report) and Finch Therapeutics Group (NASDAQ:FNCH – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.
Risk and Volatility
Organon & Co. has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500.
Profitability
This table compares Organon & Co. and Finch Therapeutics Group’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Organon & Co. | 3.41% | 88.97% | 6.03% |
| Finch Therapeutics Group | N/A | -69.14% | -26.92% |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Organon & Co. | 2 | 5 | 0 | 0 | 1.71 |
| Finch Therapeutics Group | 0 | 0 | 0 | 0 | 0.00 |
Organon & Co. presently has a consensus target price of $11.40, indicating a potential downside of 16.02%. Given Organon & Co.’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Organon & Co. is more favorable than Finch Therapeutics Group.
Valuation and Earnings
This table compares Organon & Co. and Finch Therapeutics Group”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Organon & Co. | $6.22 billion | 0.57 | $187.00 million | $0.77 | 17.63 |
| Finch Therapeutics Group | N/A | N/A | -$74.75 million | ($8.82) | -0.83 |
Organon & Co. has higher revenue and earnings than Finch Therapeutics Group. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
77.4% of Organon & Co. shares are held by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are held by institutional investors. 1.6% of Organon & Co. shares are held by company insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Organon & Co. beats Finch Therapeutics Group on 11 of the 12 factors compared between the two stocks.
About Organon & Co.
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
About Finch Therapeutics Group
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.
Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.
